BioMarin Pharmaceutical Inc. (LON:0HNC)
London · Delayed Price · Currency is GBP · Price in USD 52.84
+1.03 (1.99%)
At close: Oct 31, 2025
BioMarin Pharmaceutical Market Cap
BioMarin Pharmaceutical has a market cap or net worth of 7.72 billion as of November 3, 2025. Its market cap has decreased by -24.82% in one year.
Market Cap
7.72B
Enterprise Value
7.06B
Revenue
2.30B
Ranking
n/a
PE Ratio
19.95
Stock Price
52.84
Market Cap Chart
Since July 23, 1999, BioMarin Pharmaceutical's market cap has increased from 283.77M to 7.72B, an increase of 2,621.83%. That is a compound annual growth rate of 13.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 31, 2025 | 7.84B | -21.69% |
| Dec 31, 2024 | 10.01B | -29.83% |
| Dec 29, 2023 | 14.26B | -10.67% |
| Dec 30, 2022 | 15.96B | 33.26% |
| Dec 31, 2021 | 11.98B | 2.74% |
| Dec 31, 2020 | 11.66B | 1.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 191.73B |
| GSK plc | 71.57B |
| Haleon | 31.54B |
| Smith & Nephew | 11.91B |
| ConvaTec Group | 4.85B |
| Hikma Pharmaceuticals | 4.07B |
| HUTCHMED (China) | 2.01B |
| Genus | 1.68B |